KT-253
1 clinical trial
1 abstract
4 indications
Indication
Myeloid NeoplasmsIndication
Acute Lymphocytic LeukemiaIndication
LymphomaIndication
CancerClinical trial
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-11-01